Insider Transactions in Q4 2021 at Selecta Biosciences Inc (SELB)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
211,190
+0.9%
|
$422,380
$2.99 P/Share
|
|
Dec 13
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
14,592
+0.06%
|
$29,184
$2.98 P/Share
|
|
Dec 10
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
17,196
-5.33%
|
$34,392
$2.99 P/Share
|
|
Dec 10
2021
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
4,370
-3.93%
|
$8,740
$2.99 P/Share
|
|
Dec 10
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,370
-2.14%
|
$8,740
$2.99 P/Share
|
|
Dec 10
2021
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,083
-2.42%
|
$8,166
$2.99 P/Share
|
|
Dec 10
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
58,681
+0.25%
|
$117,362
$2.99 P/Share
|
|
Dec 09
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
3,748,000
+14.06%
|
$11,244,000
$3.06 P/Share
|
|
Dec 08
2021
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+10.42%
|
-
|
|
Dec 08
2021
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+11.01%
|
-
|
|
Dec 08
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+6.31%
|
-
|
|
Dec 08
2021
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+7.55%
|
-
|
|
Dec 03
2021
|
Carrie Smith Cox Director |
BUY
Open market or private purchase
|
Direct |
17,200
+17.19%
|
$34,400
$2.95 P/Share
|
|
Dec 02
2021
|
Nishan M De Silva Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$14,000
$2.96 P/Share
|
|
Dec 02
2021
|
Kevin Tan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.03 P/Share
|
|
Dec 02
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,746
-1.64%
|
$9,492
$2.96 P/Share
|
|
Dec 01
2021
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+3.64%
|
-
|
|
Oct 13
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
15,313
-5.21%
|
$61,252
$4.39 P/Share
|
|
Oct 13
2021
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
3,892
-3.84%
|
$15,568
$4.39 P/Share
|
|
Oct 13
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,892
-2.0%
|
$15,568
$4.39 P/Share
|
|
Oct 13
2021
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,636
-2.3%
|
$14,544
$4.39 P/Share
|
|
Oct 01
2021
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+11.31%
|
-
|
|
Oct 01
2021
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+11.96%
|
-
|
|
Oct 01
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+6.61%
|
-
|
|
Oct 01
2021
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+7.99%
|
-
|